Your browser doesn't support javascript.
loading
MiR-106a* inhibits oral squamous cell carcinoma progression by directly targeting MeCP2 and suppressing the Wnt/ß-Catenin signaling pathway.
Zhang, Nan; Wei, Zhu-Liang; Yin, Jing; Zhang, Lu; Wang, Jin; Jin, Zuo-Lin.
Affiliation
  • Zhang N; State Key Laboratory of Military Stomatology & National Clinical Research Center for Oral Diseases & Shaanxi Clinical Research Center for Oral Diseases, Department of Orthodontics, School of Stomatology, The Fourth Military Medical University Xi'an 710032, Shaanxi, China.
  • Wei ZL; Department of Stomatology, The First Affiliated Hospital of Xi'an Jiaotong University Xi'an 710061, Shaanxi, China.
  • Yin J; Department of Orthodontics, Jinan Stomatological Hospital Jinan 250001, Shandong, China.
  • Zhang L; Jinan Stomatological Hospital Jinan 250001, Shandong, China.
  • Wang J; Department of Foreign Languages, Ming De College of Northwestern Polytechnical University Xi'an 710124, Shaanxi, China.
  • Jin ZL; Department of Oral and Maxillofacial Surgery, Jinan Stomatological Hospital Jinan 250001, Shandong, China.
Am J Transl Res ; 10(11): 3542-3554, 2018.
Article de En | MEDLINE | ID: mdl-30662606
ABSTRACT
MicroRNAs (miRNAs) play critical roles in the tumorigenesis and progression of oral squamous cell carcinoma (OSCC). MiR-106a* functions as a tumor suppressor miRNA in several cancers; however, its role in OSCC has not been elucidated. We investigated the role of miR-106a* in human OSCC and explored its relevant mechanisms. The expression of miR-106a* was significantly downregulated in OSCC tissues and cell lines. The overexpression of miR-106a* inhibited OSCC cell proliferation and the cell cycle G1-S transition, and induced apoptosis. In contrast, inhibition of miR-106a* promoted cell proliferation and G1-S transition and suppressed apoptosis. The expression of miR-106a* inversely correlated with methyl-CpG binding protein 2 (MeCP2) expression in OSCC tissues. Using a luciferase reporter assay, MeCP2 was determined to be a direct target of miR-106a*. Overexpression of miR-106a* decreased MeCP2 expression at both the mRNA and protein levels, while inhibition of miR-106a* increased MeCP2 expression. Importantly, overexpression of MeCP2 eliminated the effects of miR-106a* overexpression in OSCC cells and silencing of MeCP2 recapitulated the cellular and molecular effects observed with miR-106a* overexpression. MeCP2 may promote OSCC cell proliferation by activating the Wnt/ß-Catenin signaling pathway. Taken together, our study demonstrated that miR-106a* inhibited OSCC cell proliferation by suppression of the Wnt/ß-Catenin signaling pathway and induced apoptosis through regulation of Caspase 3/9 expression via targeting MeCP2. These findings suggest that miR-106a* acted as a tumor suppressor in the progression of OSCC and may be a potential new target for OSCC diagnosis and therapy.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Am J Transl Res Année: 2018 Type de document: Article Pays d'affiliation: Chine

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: Am J Transl Res Année: 2018 Type de document: Article Pays d'affiliation: Chine
...